Available within the type of a nasal spray, it’s designed to kill the virus within the higher airways, stopping it from incubating and spreading to the lungs

Canadian biotech agency SaNOtize Research & Development Corp. has entered into an unique long run settlement with Glenmark Pharmaceuticals Ltd for the manufacturing, advertising and marketing and distribution of its breakthrough Nitric Oxide Nasal Spray (NONS) for COVID-19 remedy in India.

Glenmark can even be dealing with different Asian markets together with Singapore, Malaysia, Hong Kong, Taiwan, Nepal, Brunei, Cambodia, Laos, Myanmar, Sri Lanka, Timor-Leste and Vietnam.

“In March 2021, SaNOtize’s clinical trials showed NONS was a safe and effective antiviral treatment to prevent the transmission of COVID-19, shorten its course, and reduce the severity of symptoms,” Glenmark stated in an announcement.

“In the first 24 hours, NONS reduced the average viral load by around 95%, and then by more than 99% within 72 hours. It has been tested in healthy volunteers and patients as part of U.K. and Canada clinical trials,” it stated.

Available within the type of a nasal spray, it’s designed to kill the virus within the higher airways, stopping it from incubating and spreading to the lungs.

It is predicated on nitric oxide (NO), a pure nano- molecule with confirmed anti-microbial properties, and which has a direct impact on SARS-CoV-2, the virus inflicting COVID-19, the corporate stated.

In early July 2021, Glenmark had introduced a proposal to the Subject Expert Committee of CDSCO for emergency approval for import and advertising and marketing of the nasal spray.

“The committee has recommended a Phase III clinical trial to be conducted in Indian patients in the weeks to follow,” Glenmark stated.

The Phase III medical trial for NONS is predicted to be accomplished, adopted by industrial introduction underneath the model identify FabiSpray in India, by fourth quarter of the calendar 12 months 2021.

“Our efforts since the beginning of COVID-19 have been to provide patients with safe and effective treatment options to fight the disease,” stated Glenn Saldanha, Chairman & MD, Glenmark Pharmaceuticals Ltd.

“This partnership with SaNOtize closely aligns with our focused approach against COVID-19 and will help reduce the burden of the pandemic in the region,” he stated.

“It also marks another valuable in-licensing opportunity for us in our key therapy area of respiratory medicine, as well as the possibility to globally supply the product to SaNOtize and its partners outside of our territory,” he stated.

“COVID-19 and its various variants are proving to be a challenge to contain despite the rapid – and critical – development of vaccines,” stated Dr. Gilly Regev, CEO & Co-founder of SaNOtize.

“In joining forces with Glenmark, SaNOtize can accelerate the efforts to have its antiviral nasal spray available as a self-administered, first line of defence against COVID-19 during the current pandemic and to help prevent future outbreaks,” she stated.

NONS is likely one of the few novel therapeutic therapies, exterior of pricy monoclonal antibodies, that’s confirmed to cut back SARS-CoV-2 viral load in people, Glenmark stated.


Please enter your comment!
Please enter your name here